ACE2 and COVID-19: This effect of COVID-19 on patients with pre-existing liver disease can be explained with findings that SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) receptors, which are expressed in hepatocytes and cholangiocytes.